{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:26:33Z","timestamp":1792491993126,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["VEO-001040"],"award-info":[{"award-number":["VEO-001040"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128770","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:55:30Z","timestamp":1782384930000},"page":"128770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18\u201349\u00a0years at increased risk for severe RSV disease"],"prefix":"10.1016","volume":"88","author":[{"given":"David","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Dubois de Gennes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Biundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Verelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128770_bb0005","unstructured":"CDC [Internet]. Clinical overview of RSV. [updated 18 August 2025; cited 27 August 2025]. Available from: https:\/\/www.cdc.gov\/rsv\/hcp\/clinical-overview\/index.html."},{"key":"10.1016\/j.vaccine.2026.128770_bb0010","unstructured":"FDA [Internet]. Respiratory syncytial virus (RSV). [updated 22 October 2024; cited 27 March 2026]. Available from: https:\/\/www.fda.gov\/consumers\/covid-19-flu-and-rsv\/respiratory-syncytial-virus-rsv."},{"issue":"6","key":"10.1016\/j.vaccine.2026.128770_bb0015","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/irv.12912","article-title":"Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017-2019","volume":"16","author":"Choi","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128770_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.44756","article-title":"Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023","volume":"7","author":"Havers","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128770_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac300","article-title":"Rates of medically attended RSV among US adults: a systematic review and meta-analysis","volume":"9","author":"McLaughlin","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128770_bb0035","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128770_bb0040","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128770_bb0045","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128770_bb0050","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128770_bb0055","unstructured":"CDC [Internet]. RSV in adults. [updated 20 February 2026; cited 26 March 2026]. Available from: https:\/\/www.cdc.gov\/rsv\/adults\/index.html."},{"key":"10.1016\/j.vaccine.2026.128770_bb0060","unstructured":"FDA [Internet]. Approval letter \u2013 AREXVY. Prescribing information [published 13 March 2026; cited 26 March 2026]. Available from: https:\/\/www.fda.gov\/media\/191552\/download?attachment."},{"key":"10.1016\/j.vaccine.2026.128770_bb0065","unstructured":"A study on the immune response and safety of vaccine against respiratory syncytial virus (RSV) given to adults 18 to 49 Years of age at increased risk for respiratory syncytial virus disease, compared to older adults 60 years of age and above. Clinicaltrials.gov identifier: NCT06389487. [updated 4 April 2025; cited 4 September 2025]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06389487."},{"key":"10.1016\/j.vaccine.2026.128770_bb0070","series-title":"Presented at the European Respiratory Society (ERS) Congress; September 27\u2013October 1,","article-title":"Immunogenicity and safety of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) up to 6 months post-vaccination in adults 18\u201349 years of age (YOA) at increased risk of RSV disease and adults \u226560 YOA","author":"Mitha","year":"2025"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128770_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70181","article-title":"Prevalence and age at diagnosis of risk factors for severe respiratory syncytial virus disease among US adults: An analysis of 2011\u20132020 NHANES data","volume":"19","author":"Horn","year":"2025","journal-title":"Influenza Other Respi Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0080","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2432745","article-title":"Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged \u226560 years in the United States","volume":"20","author":"La","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128770_bb0085","doi-asserted-by":"crossref","unstructured":"La E., Singer D., Dubois de Gennes C., Graham J., Grace M., Poston S., Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged \u226560 years with diabetes. Presented at the American Diabetes Association (ADA) Scientific Sessions; June 20\u201323, 2025; Chicago, IL, US.","DOI":"10.2337\/db25-1053-P"},{"key":"10.1016\/j.vaccine.2026.128770_bb0090","doi-asserted-by":"crossref","unstructured":"La E., Singer D., Dubois de Gennes C., Graham J., Grace M., Poston S., Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged \u226560 yearswith cardiopulmonary disease. Presented at The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference; May 13\u201316, 2025; Montreal, Quebec, Canada.","DOI":"10.1016\/j.jval.2025.04.426"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128770_bb0095","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s40121-025-01238-8","article-title":"Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among adults in the USA aged 50\u201359 years at increased risk of severe RSV disease","volume":"14","author":"Singer","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/14760584.2025.2539893","article-title":"Public health impact of RSV vaccination among adults aged 60years and older in the United States using real-world evidence from the initial post-introduction season","volume":"24","author":"Verelst","year":"2025","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128770_bb0105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128770_bb0110","unstructured":"CDC [Internet]. How RSV spreads. [updated 8 July 2025; cited 27 August 2025]. Available from: https:\/\/www.cdc.gov\/rsv\/causes\/index.html."},{"key":"10.1016\/j.vaccine.2026.128770_bb0115","unstructured":"US Census Bureau [Internet]. Projected population by single year of age, sex, race, and Hispanic origin for the United States: 2023 to 2100. 2023. [cited 22 May 2024]. Available from: https:\/\/www.census.gov\/data\/datasets\/2023\/demo\/popproj\/2023-popproj.html."},{"key":"#cr-split#-10.1016\/j.vaccine.2026.128770_bb0120.1","unstructured":"CDC [Internet]. Flu vaccination coverage, United States, 2023-24 influenza season. [updated 20 September 2024"},{"key":"#cr-split#-10.1016\/j.vaccine.2026.128770_bb0120.2","unstructured":"cited 7 October 2024]. Available from: https:\/\/www.cdc.gov\/fluvaxview\/coverage-by-season\/2023-2024.html."},{"key":"10.1016\/j.vaccine.2026.128770_bb0125","unstructured":"US Bureau of Economic Analysis [Internet]. FRED GDP deflator, 2024. [cited 5 June 2024]. Available from: https:\/\/fred.stlouisfed.org\/series\/GDPDEF\/."},{"key":"10.1016\/j.vaccine.2026.128770_bb0130","unstructured":"US Bureau of Labor Statistics [Internet]. Consumer price index for all urban consumers: Medicare care in US city average, not seasonally adjusted (half 1 2024). 2024. [cited 7 October 2024]. Available from: https:\/\/www.bls.gov\/cpi\/data.htm."},{"issue":"10","key":"10.1016\/j.vaccine.2026.128770_bb0135","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128770_bb0140","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0145","doi-asserted-by":"crossref","DOI":"10.1080\/20016689.2020.1857052","article-title":"An algorithm to generate correlated input-parameters to be used in probabilistic sensitivity analyses","volume":"9","author":"Neine","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.vaccine.2026.128770_bb0150","unstructured":"Institute for Clinical and Economic Review [Internet]. ICER 2019 perspectives on cost-effectiveness threshold ranges [updated August 2023; cited 26 March 2026]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2023\/08\/ICER_2019_Perspectives-on-Cost-Effectiveness-Threshold-Ranges.pdf."},{"issue":"9","key":"10.1016\/j.vaccine.2026.128770_bb0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128770_bb0160","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.50634","article-title":"Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 pandemic","volume":"6","author":"Juhn","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128770_bb0170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","article-title":"Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States","volume":"40","author":"Herring","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/infdis\/jiaa331","article-title":"Epidemiology of respiratory syncytial virus across five influenza seasons among adults and children one year of age and older-Washington State, 2011\/2012-2015\/2016","volume":"223","author":"Jackson","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128770_bb0180","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/cid\/ciab131","article-title":"Incidence of medically attended acute respiratory illnesses due to respiratory viruses across the life course during the 2018\/19 influenza season","volume":"73","author":"Jackson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128770_bb0185","unstructured":"Quinn E., Sato R., Atwood M., Begier E., Cane A., Chilson E. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine in high-risk adults aged 19-59 years in the United States (US). Presented at the 13th International RSV Symposium; March 12\u201315, 2025; Iguazu Falls, Brazil."},{"issue":"5","key":"10.1016\/j.vaccine.2026.128770_bb0190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/irv.12258","article-title":"Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status","volume":"8","author":"Matias","year":"2014","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2026.128770_bb0195","unstructured":"CDC [Internet]. Fast facts: health and economic costs of chronic conditions. [updated 8 Aug 2025; cited 2 September 2025]. Available from: https:\/\/www.cdc.gov\/chronic-disease\/data-research\/facts-stats\/index.html."},{"issue":"4","key":"10.1016\/j.vaccine.2026.128770_bb0200","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","article-title":"Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study","volume":"12","author":"Li","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128770_bb0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/infdis\/jiad012","article-title":"Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis","volume":"228","author":"Onwuchekwa","year":"2023","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128770_bb0210","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s40121-023-00805-1","article-title":"Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR","volume":"12","author":"Ramirez","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JCM.05841-11","article-title":"Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness","volume":"50","author":"Falsey","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128770_bb0220","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/jmv.23937","article-title":"Comparison of sputum and nasopharyngeal swabs for detection of respiratory viruses","volume":"86","author":"Jeong","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2026.128770_bb0225","doi-asserted-by":"crossref","unstructured":"Singer D., Wang Y., La E.M., Gerber S.I., Wu A., Keith A.B. Long-term clinical outcomes after hospitalization for acute respiratory illness due to respiratory syncytial virus (RSV). Clin Infect Dis 2025;ciaf710. Online ahead of print.","DOI":"10.1093\/cid\/ciaf710"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128770_bb0230","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/infdis\/jiaa361","article-title":"Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection","volume":"222","author":"Tseng","year":"2020","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128770_bb0235","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13236","article-title":"The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults \u226560years of age","volume":"18","author":"Curran","year":"2024","journal-title":"Influenza Other Resp Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128770_bb0240","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2535755","article-title":"RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023-2025 vaccination seasons","volume":"21","author":"La","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128770_bb0245","doi-asserted-by":"crossref","unstructured":"La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Presented at The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference; May 5\u20138, 2024. Atlanta, GA, US.","DOI":"10.1016\/j.jval.2024.03.738"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128770_bb0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00019053-200826020-00006","article-title":"Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness","volume":"26","author":"Prosser","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128770_bb0255","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1370\/afm.1542","article-title":"Vaccinations administered during off-clinic hours at a national community pharmacy: implications for increasing patient access and convenience","volume":"11","author":"Goad","year":"2013","journal-title":"Ann Fam Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:37:16Z","timestamp":1789504636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["S0264410X26005797"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128770","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination among US adults aged 18\u201349\u00a0years at increased risk for severe RSV disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 GSK plc.. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128770"}}